NVIDIA ignites the next battlefield: Partnering with Johnson & Johnson and Eli Lilly, the trillion-dollar pharmaceutical industry welcomes the revolution of "AI Surgery" and "Pharmaceutical Factories"

NVIDIA's CEO stated that Johnson & Johnson and Eli Lilly are leveraging NVIDIA technology to optimize products and develop new therapies. Johnson & Johnson is training surgical robots and simulating surgical processes, aiming for non-invasive surgeries in the future. NVIDIA is collaborating with Eli Lilly to build a supercomputer, serving as an "AI factory" for new drug discovery and improving drug production. Eli Lilly mentioned that by intelligently embedding workflows, they are unlocking new business models and driving medical advancements. The supercomputer will be based on the Blackwell architecture, equipped with the DGX B300 system, featuring over 1,000 B300 GPUs